RETINA MACULA INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2007-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 3
1 (33.3%)Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Proliferative Diabetic RetinopathyDiabetic Macular EdemaNon-proliferative Diabetic Retinopathy
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01571232
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01449682
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Phase 2
Completed
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Device: OCT, Multifocal ERG, Microperimetry
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 91
- Registration Number
- NCT00764738
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
News
No news found